Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States

Daniel Molnar; Elizabeth M La; Frederik Verelst; Sara Poston; Jonathan Graham; Laure-Anne Van Bellinghen; Desmond Curran

doi:10.1007/s40121-024-00939-w

Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States

Infect Dis Ther. 2024 Apr;13(4):827-844. doi: 10.1007/s40121-024-00939-w. Epub 2024 Mar 20.

Authors

Daniel Molnar¹, Elizabeth M La², Frederik Verelst³, Sara Poston², Jonathan Graham⁴, Laure-Anne Van Bellinghen⁵, Desmond Curran³

Affiliations

¹ GSK, Wavre, Belgium. daniel.h.molnar@gsk.com.
² GSK, Philadelphia, PA, USA.
³ GSK, Wavre, Belgium.
⁴ RTI Health Solutions, Research Triangle Park, NC, USA.
⁵ CHESS in Health, Bonheiden, Belgium.

Abstract

Introduction: Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract disease in older adults, resulting in substantial morbidity and mortality.

Methods: This study estimates the public health impact of vaccination with the adjuvanted RSVPreF3 vaccine among adults aged ≥ 60 years in the United States (US). A static, multi-cohort Markov model was used to estimate RSV-related outcomes over a 3-year time horizon for scenarios with and without one-time RSV vaccination. The base-case analysis assumed the same vaccination coverage as for influenza vaccines, with key epidemiology and vaccine inputs obtained from the published literature and phase 3 clinical trial results for the adjuvanted RSVPreF3 vaccine. Model outcomes included the clinical burden of RSV (symptomatic RSV acute respiratory illness [RSV-ARI] cases [classified as upper or lower respiratory tract disease], pneumonia complications, and mortality) and RSV-related healthcare resource use (hospitalizations, emergency department visits, outpatient visits, and antibiotic prescriptions).

Results: In the base-case analysis, approximately 56.7 million adults aged ≥ 60 years received the vaccine, resulting in 2,954,465 fewer symptomatic RSV-ARI cases over 3 years compared with no vaccination, including 321,019 fewer X-ray confirmed pneumonia cases and 16,660 fewer RSV-related deaths. Vaccination also prevented a substantial number of RSV-related hospitalizations (203,891), emergency department visits (164,060), outpatient visits (1,577,586), and antibiotic prescriptions (1,343,915) over the 3-year period. A considerable public health impact was observed across a range of sensitivity analyses.

Conclusions: These findings highlight the potential of the adjuvanted RSVPreF3 vaccine to substantially reduce RSV disease burden among US older adults aged ≥ 60 years.

Keywords: Adjuvanted RSVPreF3 vaccine; Healthcare resource use; Older adults; Public health impact; Respiratory syncytial virus; United States; Vaccination.